Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

被引:8
作者
Queiro, Ruben [1 ,2 ]
Seoane-Mato, Daniel [2 ]
Laiz, Ana [3 ]
Agirregoikoa, Eva Galindez [4 ]
Montilla, Carlos [5 ]
Park, Hye Sang [3 ]
Tasende, Jose Pinto A. [6 ]
Baute, Juan Jose Bethencourt [7 ]
Ibanez, BeatrizJoven [8 ]
Toniolo, Elide [9 ]
Ramirez, Julio [10 ]
Garcia-Hinojosa, Cristina Pruenza
机构
[1] Univ Oviedo, Fac Med, Rheumatol Serv, Oviedo, Spain
[2] Spanish Soc Rheumatol, Res Unit, Madrid, Spain
[3] Hosp Unive Santa Creu& Sant Pau, Rheumatol & Autoimmune Dis Dept, Barcelona, Spain
[4] Hosp Univ Basurto, Rheumatol Serv, Bilbao, Spain
[5] Hosp Univ Salamanca, Rheumatol Serv, Salamanca, Spain
[6] Complexo Hosp Univ Coruna, Rheumatol Serv, INIBIC, La Coruna, Spain
[7] Hosp Univ Canarias, Rheumatol Serv, Santa Cruz de Tenerife, Spain
[8] Hosp Univ 12 Octubre, Rheumatol Serv, Madrid, Spain
[9] Hosp Univi Son Llatzer, Rheumatol Serv, Palma De Mallorca, Spain
[10] Hosp Clin Barcelona, Rheumatol Dept, Arthrit Unit, Barcelona, Spain
关键词
recent-onset psoriatic arthritis; severe disease; global pain; perianal psoriasis; prediction model; machine learning; QUESTIONNAIRE; INVOLVEMENT;
D O I
10.3389/fmed.2022.891863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo identify patient- and disease-related characteristics that make it possible to predict higher disease severity in recent-onset PsA. MethodsWe performed a multicenter observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged >= 18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. Severe disease was defined at each visit as fulfillment of at least 1 of the following criteria: need for systemic treatment, Health Assessment Questionnaire (HAQ) > 0.5, polyarthritis. The dataset contained data for the independent variables from the baseline visit and follow-up visit number 1. These were matched with the outcome measures from follow-up visits 1 and 2, respectively. We trained a logistic regression model and random forest-type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis. ResultsThe sample comprised 158 patients. At the first follow-up visit, 78.2% of the patients who attended the clinic had severe disease. This percentage decreased to 76.4% at the second visit. The variables predicting severe disease were patient global pain, treatment with synthetic DMARDs, clinical form at diagnosis, high CRP, arterial hypertension, and psoriasis affecting the gluteal cleft and/or perianal area. The mean values of the measures of validity of the machine learning algorithms were all >= 80%. ConclusionOur prediction model of severe disease advocates rigorous control of pain and inflammation, also addressing cardiometabolic comorbidities, in addition to actively searching for hidden psoriasis.
引用
收藏
页数:9
相关论文
共 31 条
  • [1] Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
    Alonso, Sara
    Villa, Ignacio
    Fernandez, Sabela
    Martin, Jose L.
    Charca, Lilyan
    Pino, Marina
    Riancho, Leyre
    Morante, Isla
    Santos, Monserrat
    Brandy, Anahy
    Aurrecoechea, Elena
    Carmona, Loreto
    Queiro, Ruben
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [2] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
    Baraliakos, Xenofon
    Gossec, Laure
    Pournara, Effie
    Jeka, Slawomir
    Mera-Varela, Antonio
    D'Angelo, Salvatore
    Schulz, Barbara
    Rissler, Michael
    Nagar, Kriti
    Perella, Chiara
    Coates, Laura C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) : 582 - 590
  • [3] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [4] Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target
    Davis, Gwendolyn K.
    Fehrenbach, Daniel J.
    Madhur, Meena S.
    [J]. CURRENT HYPERTENSION REPORTS, 2021, 23 (03)
  • [5] Mortality in psoriatic arthritis: Risk, causes of death, predictors for death
    Elalouf, Ofir
    Muntyanu, Anastasiya
    Polachek, Ari
    Pereira, Daniel
    Ye, Justine Y.
    Lee, Ker-Ai
    Chandran, Vinod
    Cook, Richard J.
    Gladman, Dafna D.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 571 - 575
  • [6] ESTEVEVIVES J, 1993, J RHEUMATOL, V20, P2116
  • [7] Psoriasis assessment tools in clinical trials
    Feldman, SR
    Krueger, GG
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 65 - 68
  • [8] Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions
    Ferguson, Lyn D.
    Siebert, Stefan
    McInnes, Iain B.
    Sattar, Naveed
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (08) : 461 - 474
  • [9] Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis
    Garcia-Valle, Andrea
    Andres-de Llano, Jesus Maria
    Farina-Gonzalez, Aaron Josue
    Gonzalez-Benitez, Roberto Daniel
    Queiro-Silva, Ruben
    [J]. JOURNAL OF RHEUMATOLOGY, 2022, 49 (01) : 36 - 43
  • [10] Psoriatic arthritis
    Gladman, Dafna D.
    [J]. DERMATOLOGIC THERAPY, 2009, 22 (01) : 40 - 55